Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAFF4: Vernakalant vs. Procainamide for Acute Atrial Fibrillation
NCT04485195Phase 4Completed
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Jun 2021
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of vernakalant in Atrial fibrillation (AFib), sponsored by Ottawa Hospital Research Institute. Started Jun 2021; status: completed.
02
Drugs
vernakalant
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT04485195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04485195.